Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to evaluate the efficacy of plasma p-tau217 biomarkers in identifying amyloid pathology and predicting cognitive outcomes among individuals with Alzheimer's disease.
Analyzed plasma p-tau217 levels in a cohort from the Japanese Alzheimer's Disease Neuroimaging Initiative.
Evaluated the relationship between p-tau217 and amyloid pathology.
Assessed cognitive outcomes in relation to plasma biomarker levels.
Plasma p-tau217 levels are confirmed as robust biomarkers for Alzheimer's disease.
p-tau217/Aβ42 ratio shows strong correlation with amyloid pathology.
Findings suggest significant potential for these biomarkers in assessing cognitive decline.

Evaluation of plasma biomarkers reveals amyloid pathology and cognitive outcomes in Alzheimer's disease, indicating their significance.

Plasma p-tau217 and p-tau217/Aβ42 are robust biomarkers for AD diagnosis and prognosis in the Japanese population.

No takes yet. Share an insight, caveat, or question.

Kasuga et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share